Chardan Capital Markets resumes coverage on Arbutus Biopharma (NASDAQ: ABUS) with a Buy rating and a price target of $8.25.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE